Atrion (NASDAQ:ATRI) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of Atrion (NASDAQ:ATRIGet Free Report) in a research report issued to clients and investors on Thursday. The brokerage set a “sell” rating on the medical instruments supplier’s stock.

Atrion Stock Performance

NASDAQ:ATRI opened at $459.92 on Thursday. The stock’s 50-day simple moving average is $458.90 and its 200 day simple moving average is $444.77. The company has a market cap of $809.46 million, a P/E ratio of 43.23 and a beta of 0.69. Atrion has a 52-week low of $274.98 and a 52-week high of $503.24.

Atrion (NASDAQ:ATRIGet Free Report) last announced its quarterly earnings results on Thursday, August 8th. The medical instruments supplier reported $0.23 earnings per share for the quarter. The firm had revenue of $48.77 million for the quarter. Atrion had a return on equity of 7.75% and a net margin of 10.60%.

Hedge Funds Weigh In On Atrion

Institutional investors have recently bought and sold shares of the business. Quadrant Capital Group LLC acquired a new position in Atrion during the fourth quarter worth approximately $36,000. Headlands Technologies LLC bought a new stake in shares of Atrion during the second quarter worth approximately $54,000. Benjamin F. Edwards & Company Inc. bought a new stake in shares of Atrion during the second quarter worth approximately $72,000. EntryPoint Capital LLC bought a new stake in shares of Atrion during the first quarter worth approximately $91,000. Finally, Comerica Bank boosted its holdings in shares of Atrion by 60.9% during the first quarter. Comerica Bank now owns 415 shares of the medical instruments supplier’s stock worth $192,000 after acquiring an additional 157 shares during the period. Institutional investors and hedge funds own 66.19% of the company’s stock.

About Atrion

(Get Free Report)

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.

Further Reading

Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.